First IBA proton therapy center in Russia

Proton therapy

Cyclotron for four room Proteus®PLUS successfully rigged in Dimitrovgrad

Louvain-La-Neuve, Belgium, Dimitrovgrad, Russian Federation, October 19, 2016 - IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, announces the delivery and installation of the Cyclone® 230 for a new proton therapy center in Dimitrovgrad (Ulyanovsky region, Russia). The center will be a part of the Federal High-Tech Center of Medical Radiology of the Federal Medico-Biological Agency of Russia (FMBA)

IBA will equip the center with the Proteus®PLUS* four-treatment room configuration, which provides the best in class treatment with Image Guided Intensity Modulated Proton Therapy (IMPT).

The installation of the facility started in August 2016. The acceptance of the first treatment room is planned for the end of 2017. The proton therapy center in Dimitrovgrad will be IBA’s first in the Russian Federation and is expected to treat up to 1,200 patients per year.

The Head of FMBA, Mr. Vladimir Uiba, Governor of Ulaynovsky region, Mr. Sergey Morozov, and local media were in attendance at this important event for IBA, FMBA and Russia. Representing IBA was Vice-President and the Director of the IBA’s Representative office in Russia, CIS Mr. Kirill Makarenko, as well as the wider IBA site team. 

Mr. Vladimir Uiba, Head of FMBA of Russia
, emphasized: ''This is a historical event not only for the Ulyanovsky region but also for the whole country. The proton therapy technology produced by IBA is ground-breaking and highly-praised also by the scientists and specialists in the Joint Institute of Nuclear Research in Dubna. Proton therapy is a unique method for cancer treatment and it is at the cutting edge of innovation in oncology."

Kirill Makarenko, Vice-President of IBA and Director of the IBA’s Representative office in Russia
, commented on this achievement and its importance for the Russian region: “There are around 500,000 new cancer cases diagnosed in Russia every year and many of them could be treated with proton therapy. The center in Dimitrovgrad will be the first of its kind available to cancer patients from the Ulyanovsky region and the whole Privolzhsky Federal District.”

* Proteus
®PLUS is the brand name of a Proteus®235 configuration.




Watch a video about this event on the Russia TV Channel:

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About Federal Medico-Biological Agency of Russia
Federal Medico-Biological Agency of Russia (FMBA) is the state authority specializing in delivering state services and management of state institutions in the field of health care (research activities, sport medicine and others). FMBA is the part of the Ministry of Health of Russia. FMBA manages more than 200 federal budget institutions all over Russia, each institution may consist of several smaller medical and/or research institutions.The Federal Center of Nuclear Medicine Projects Design & Development of FMBA is the Customer of PTC equipment in Dimitrovgrad.
About Federal High-Tech Center of Medical Radiology of FMBA (FHTCMR)
FHTCMR includes more than 20 buildings such as: Proton Therapy Center, PET-center, hospital, convalescent center, radionuclide diagnosis department, polyclinic and others. FHTCMR is subject to final acceptance in 2018, some buildings will be accepted and may start operating in 2017.

Area occupied by buildings: 35 688,79 m2. Total buildings area: 105 297,1 m2. Estimated number of medical and operating personnel: 1430. FHTCMR will be able to deliver medical care to 40 000 patients per year. Amount of investments: more than 19 billion rubles. FHTCMR is the project of federal importance. Purposes of the project: saved lives, economy growth of the region, delivering of high-tech medical care, training of highly-qualified specialists in radiology, medical physics and so on.